Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease
Top Cited Papers
- 17 July 2001
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 135 (2) , 73-87
- https://doi.org/10.7326/0003-4819-135-2-200107170-00007
Abstract
To examine the efficacy of ACE inhibitors for treatment of nondiabetic renal disease. 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens including ACE inhibitors to the efficacy of regimens without ACE inhibitors in predominantly nondiabetic renal disease. Studies were identified by searching the MEDLINE database for English-language studies evaluating the effects of ACE inhibitors on renal disease in humans between May 1977 (when ACE inhibitors were approved for trials in humans) and September 1997. Data on 1860 nondiabetic patients were analyzed. Mean duration of follow-up was 2.2 years. Patients in the ACE inhibitor group had a greater mean decrease in systolic and diastolic blood pressure (4.5 mm Hg [95% CI, 3.0 to 6.1 mm Hg]) and 2.3 mm Hg [CI, 1.4 to 3.2 mm Hg], respectively) and urinary protein excretion (0.46 g/d [CI, 0.33 to 0.59 g/d]). After adjustment for patient and study characteristics at baseline and changes in systolic blood pressure and urinary protein excretion during follow-up, relative risks in the ACE inhibitor group were 0.69 (CI, 0.51 to 0.94) for end-stage renal disease and 0.70 (CI, 0.55 to 0.88) for the combined outcome of doubling of the baseline serum creatinine concentration or end-stage renal disease. Patients with greater urinary protein excretion at baseline benefited more from ACE inhibitor therapy (P = 0.03 and P = 0.001, respectively), but the data were inconclusive as to whether the benefit extended to patients with baseline urinary protein excretion less than 0.5 g/d. Antihypertensive regimens that include ACE inhibitors are more effective than regimens without ACE inhibitors in slowing the progression of nondiabetic renal disease. The beneficial effect of ACE inhibitors is mediated by factors in addition to decreasing blood pressure and urinary protein excretion and is greater in patients with proteinuria. Angiotensin-converting inhibitors are indicated for treatment of nondiabetic patients with chronic renal disease and proteinuria and, possibly, those without proteinuria. *For other members of the ACE Inhibition in Progressive Renal Disease Study Group, see Appendix 1.Keywords
This publication has 35 references indexed in Scilit:
- The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme InhibitorsAnnals of Internal Medicine, 1999
- Use of Enalapril To Attenuate Decline in Renal Function in Normotensive, Normoalbuminuric Patients with Type 2 Diabetes MellitusAnnals of Internal Medicine, 1998
- Antilymphocyte Antibodies, Renal Transplantation, and Meta-AnalysisAnnals of Internal Medicine, 1998
- Effect of Angiotensin-Converting Enzyme Inhibitors on the Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 1997
- Renal Parenchymal HypertensionArchives of internal medicine (1960), 1996
- Long-term Renoprotective Effect of Angiotensin-converting Enzyme Inhibition in Non—insulin-dependent Diabetes MellitusArchives of internal medicine (1960), 1996
- The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuriaThe American Journal of Medicine, 1995
- Report on a workshop to develop management recommendations for the prevention of progression in chronic renal diseaseAmerican Journal of Kidney Diseases, 1995
- Long-Term Effects of Enalapril and Nicardipine on Urinary Albumin Excretion in Patients with Chronic Renal Insufficiency: A 1-Year Follow-UpAmerican Journal of Nephrology, 1991
- Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.BMJ, 1988